Han Xu

Dec 5, 2024 | onlinelibrary.wiley.com | Han Xu |Jianhua Han |Anirudh Sharma

Conflict of Interest The authors declare no conflict of interest. References 1, , Renew. Sustain. Energy Rev. 2016, 62, 1092. 2, Joule 2021, 5, 2521. 3, , , , , Nat. Mater. 2023, 22, 1304. 4a) , , , , , , , , , , , , , , , , ACS Energy Lett. 2022, 7, 2927; b) , , , , J. Mater. Chem. C 2020, 8, 13422; c) , , , , , , , Adv. Mater. Technol. 2020, 5, 2000226; d) , , , , , , , , , , , Nat. Energy 2023, 8, 62; e) , , , , , , , Adv. Funct. Mater. 2021, 31, 2009996. 5, , , , , , , , , , Org. Electron.

Aug 30, 2024 | chemistry-europe.onlinelibrary.wiley.com | Han Xu |Cong-Zhi Wang |Qun-yan Wu |Jian-hui Lan

Supporting Information As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Filename Description ejic202400386-s1-Supporting_Information.pdf590.3 KB Supplementary

May 6, 2024 | onlinelibrary.wiley.com | Han Xu |Yusen Ye |Ran Duan |Yong Gao

1 Introduction With the advancement of high-throughput single-cell sequencing technologies and the decreasing cost of experiments, large-scale projects such as Human Cell Atlas,[1] Mouse Cell Atlas,[2] Tabula Muris,[3] and Accelerating Medicines Partnership[4-6] have successfully obtained transcriptional profiling for hundreds of thousands of cells.

Oct 4, 2023 | onlinelibrary.wiley.com | Han Xu |Shuai Chen |RenZhi Hu |Muqun Hu

Yong Chen Center for Advanced Manufacturing, University of Southern California, Los Angeles, CA, 90007 USA Daniel J. Epstein Department of Industrial and Systems Engineering, University of Southern California, Los Angeles, CA, 90089 USA Department of Aerospace and Mechanical Engineering, University of Southern California, Los Angeles, CA, 90089 USASearch for more papers by this author

Sep 25, 2023 | onlinelibrary.wiley.com | Han Xu |Longzhi Li |Bing Dong |Ji Lu

1 INTRODUCTION In breast cancer, which is the most frequent malignancy in women,1 triple-negative breast cancer (TNBC), detected as negative expression of estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 receptor (HER2) by immunohistochemistry, is easy to relapse and metastasize.2 Given a lack of effective endocrinotherapy and molecular targeted therapy, the main treatment option is chemotherapy for TNBC.3, 4 However, TNBC patients usually develop...